A bifunctional fusion membrane-based biocompatible nanovaccine to potentiate cancer immunotherapy
Theranostics · 21.04.2025 · 15 (12) · 5719-5737
DOI: 10.7150/thno.106376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 21.04.2025. Verfasst von Wei Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cancer cell membrane-based nanovaccines derived from patients' tumor tissues have shown promising features as a personalized cancer treatment strategy. However, the weak immunogenicity of autologous tumor antigens undermines the therapeutic effects of personalized vaccines.
Methods
We synthesized a biomimetic nanovaccine, Bio-HCP@FM-NPs, composed of senescent tumor cell membranes, Escherichia coli cytoplasmic membrane extracts, and granulocyte-macrophage colony-stimulating factor (GM-CSF)-encapsulated biocompatible hypercross-linked polymer nanoparticles. The nanovaccine's antitumor and enhanced immunotherapy effects were demonstrated in multiple tumor models. The tumor prevention effects of nanovaccine were assessed using a postoperative recurrence model.
Results
The Bio-FM@HCP-NP vaccine showed promising therapeutic efficacy in the B16-F10 melanoma mouse model and significantly synergized with anti-PD-1 immunotherapy across multiple tumor models. Mechanistically, GM-CSF was promptly released to recruit naïve DCs to the nanovaccine. Thereafter, immature DCs were vigorously activated by FM-NPs, thereby activating the cytotoxic T cells. Furthermore, Bio-HCP@FM-NPs induced robust antigen-specific immune responses, prolonging postoperative survival in mice and providing long-term protection against tumor recurrence. Targeted depletion of immune cell populations revealed that T and B cells were essential for vaccine-induced tumor regression.
Conclusion
The Bio-HCP@FM-NPs showed significant promise for immunotherapy and tailored postoperative treatment of cancer, leveraging the strong activation of innate immunity by senescent tumor cell membranes and bacterial cytoplasmic membrane extracts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
- Department of Polymer, School of Material Science and Engineering, Hubei University, Wuhan, Hubei 430062, China.
Zitieren
APA
Fu, W., Cai, X., Yang, J., Yang, L., Pan, Y., & Tuo, Z. (2025). A bifunctional fusion membrane-based biocompatible nanovaccine to potentiate cancer immunotherapy. Theranostics, 15(12), 5719-5737. https://doi.org/10.7150/thno.106376
Vancouver
Fu W, Cai X, Yang J, Yang L, Pan Y, Tuo Z. A bifunctional fusion membrane-based biocompatible nanovaccine to potentiate cancer immunotherapy. Theranostics. 2025;15(12):5719-5737. doi:10.7150/thno.106376
BibTeX
@article{Fu2025,
author = {Fu, Wei and Cai, Xing and Yang, Jinru and Yang, Lian and Pan, Yaoyu and Tuo, Zhan},
title = {A bifunctional fusion membrane-based biocompatible nanovaccine to potentiate cancer immunotherapy},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {12},
pages = {5719--5737},
doi = {10.7150/thno.106376}
}
EUVIMED